Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TPG Places a Growth Bet On China's Drug Industry (China)

This article was originally published in PharmAsia News

Executive Summary

TPG, the private-equity firm formerly known as Texas Pacific Group, is investing in Shanghai ChemPartner, one of China's largest pharmaceutical-research outsourcing companies. TPG also will invest in ChemPartner's sister company, ChemExplorer, because the minority stake TPG is taking will actually be in ShangPharma, the recently formed holding company of both. ChemExplorer does most of its work for Eli Lilly & Co., while ChemPartner is an established outsourcer to many global drug firms. Multinational pharmaceutical firms are increasingly using Chinese scientists, and health care is drawing greater interest from venture capitalists and early-stage financiers, who previously avoided China's drug industry. (Click here for more - May Require Paid Subscription

You may also be interested in...

Shanghai ChemPartner CEO Michael Hui On Finding A Niche In China Amidst Increasing Foreign Competition: An Interview With PharmAsia News (Part 1 of 2)

Shanghai ChemPartner was set up in 2003 at Shanghai's Zhangjiang Hi-Tech Park, and today it is one of the leading R&D outsourcing providers in China. PharmAsia News recently visited company headquarters to meet Michael Hui, CEO of ChemPartner - as well as sister company ChemExplorer, and their holding company ShangPharma - to discuss the company's recent deal with private equity investment firm TPG, as well as handling increased competition from foreign firms moving into China.

‘Ready For Day 1’ – UK MHRA’s Statement Of Intent For Post-Brexit Medtech Regulatory System

The MHRA has been working all hours to ensure the standalone medtech UKCA mark works operationally and procedurally in the UK as of 1 January 2021.

African Platform Eyes $750m Investment

Development Partners International, CDC Group and the European Bank for Reconstruction and Development have collaborated to create a “first of its kind, pan-African” generics platform built on the acquisition and combination of Egypt’s Adwia Pharmaceuticals and India’s Celon Laboratories. An initial $250m investment is to be followed by up to $500m in further funding.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts